To include your compound in the COVID-19 Resource Center, submit it here.

FDA delays end to regulatory stand-off

The FDA said it does not intend to regulate the Genzyme Tissue Repair division's Carticel cartilage cell service at this time, but has decided to hold a

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE